PROVO, Utah, Nov. 16, 2011 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) updated its fourth quarter 2011 and recently-issued 2012 financial guidance in advance of its annual investor day later today. The company increased its fourth quarter revenue guidance to $475 to $485 million, and earnings per share by $0.02 to $0.68 to $0.72. The company also increased 2012 revenue guidance to $1.80 to $1.83 billion with earnings per share of $2.82 to $2.92.
"As we come to the conclusion of another record year, we continue to build momentum for the future," said Truman Hunt, president and chief executive officer. "We are revolutionizing the fight against aging through our ageLOC product pipeline, innovating in our direct selling channel, experiencing stellar growth in emerging markets, and continuing to drive shareholder value through improved efficiencies and increasing cash flow.
"We are experiencing a very positive response from our distributor force following our global convention and the initial limited-time-offering of our new anti-aging products," Hunt continued. "The fourth quarter is shaping up even stronger than our initial forecast, and we have confirmed the amount of new products that will be shipped in January – allowing us to increase our guidance for the quarter and for 2012.
"In short, we are succeeding because our strategy is sound and because we continue to improve our execution. We look forward to sharing our vision of the future with our shareholders at our annual investor day meeting later today," concluded Hunt.
The annual investor day presentation will be held today at 9 a.m. at the Waldorf Astoria hotel in New York City. A webcast of the event, including the financial information to be presented, will be available at http://ir.nuskin.com. A replay of the webcast, along with accompanying slides, will be made available from the same location through Dec. 31.
Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company, evidenced in its unique ageLOC™ science that addresses aging at its source. The company's anti-aging products feature the new ageLOC suite of products including the ageLOC R2 nutritional supplement, ageLOC Galvanic Spa System and Galvanic Body Spa™, as well as the ageLOC Transformation daily skin care system. A global direct selling company, Nu Skin operates in 52 markets worldwide and has more than 830,000 independent distributors. Nu Skin is traded on the New York Stock Exchange under the symbol "NUS." More information is available at http://www.nuskin.com.
Please note: This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that represent the company's current expectations and beliefs, including, among other things: (i) management's positive outlook for the company; (ii) management's expectations regarding the company's initiatives, strategies and new products; and (iii) management's projections regarding revenue and earnings per share. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following: (a) any failure of current or planned initiatives or products to generate interest among distributors and customers and generate sponsoring and selling activities on a sustained basis, including in Japan and the United States where we have experienced declines in our distributor numbers; (b) challenging economic conditions globally; (c) risk of foreign currency fluctuations and the currency translation impact on our business associated with these fluctuations; (d) risks related to general disruption and market conditions following disasters in Japan and the risk that the resulting impact on the company's operations in that market and on the ability of the company's distributors to maintain their business and sponsoring activities may negatively impact our revenues more than anticipated; (e) uncertainty regarding the impact on our business of increased regulatory scrutiny of the direct selling industry in Japan and our efforts to increase distributor compliance efforts in this market; (f) risks associated with increased general inquiries and complaints to consumer protection agencies in Japan regarding the activities of some distributors; (g) regulatory risks associated with the company's products, which could inhibit the company's ability to market a product in a market if it is determined to be a medical device in any market, if distributors make unauthorized claims that would cause such products to be classified as drugs, or if the company is unable to obtain necessary product registrations in a timely manner; (h) continued regulatory scrutiny and investigations in Mainland China, which have from time to time in the past, and could in the future, negatively impact the company's business, including the interruption of sales activities in stores, loss of licenses, and the imposition of fines; (i) adverse publicity related to the company's business, products, industry or any legal actions or complaints by distributors or others; (j) any prospective or retrospective increases in duties on our products imported into our markets outside of the United States and any adverse results of tax audits or unfavorable changes to tax laws in our various markets; and (k) continued competitive pressures in the company's markets. The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date of this release, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
SOURCE Nu Skin Enterprises, Inc.